What SURPASS-2 Actually Changes in Clinical Practice

At a glance

Detail	Value
N	1,879
Population	Adults with T2D on metformin, A1C 7.0%, 10.5%
Intervention	Tirzepatide 5 mg, 10 mg, or 15 mg SC weekly
Comparator	Semaglutide 1 mg SC weekly
Duration	40 weeks
Primary endpoint	Change from baseline in A1C
Key result	All tirzepatide doses were non-inferior and superior to semaglutide 1 mg for A1C reduction (estimated treatment difference: -0.15% at 5 mg, -0.39% at 10 mg, -0.45% at 15 mg; p < 0.001 for superiority at all doses)

Why This Trial Matters More Than Most Head-to-Heads

Most head-to-head diabetes trials compare a new drug against placebo or an older standard. SURPASS-2 did something harder: it put tirzepatide directly against semaglutide 1 mg, which was already the top-performing injectable GLP-1RA on the market. That design choice made the results immediately actionable for clinicians who were already comfortable prescribing semaglutide and needed to know whether switching or starting with tirzepatide was worth it.

The trial was powered for both non-inferiority and superiority on A1C, and it cleared both bars at all three tirzepatide doses. That is a high statistical hurdle. It also reported weight loss as a key secondary endpoint, which matters because payers, patients, and guidelines increasingly treat glycemic control and weight management as linked goals in T2D.

Methodology Details That Shape Interpretation

Dose Selection and the Semaglutide 1 mg Question

The comparator was semaglutide 1 mg, not 2 mg. At the time the trial was designed, 1 mg was the approved and most commonly used dose. Semaglutide 2 mg (approved later via SUSTAIN FORTE) did not exist as a marketed option. Critics have pointed out that comparing tirzepatide 15 mg against semaglutide 1 mg is not a symmetric dose comparison. That criticism is fair, but it does not erase the clinical relevance: the 5 mg tirzepatide dose, the lowest tested, still beat semaglutide 1 mg on A1C. The 5 mg-to-1 mg comparison is the most conservative and still showed superiority.

Titration Schedule

Tirzepatide arms started at 2.5 mg and escalated every 4 weeks. Semaglutide started at 0.25 mg, moved to 0.5 mg at week 4, and reached 1 mg at week 8. Both schedules mirror their respective prescribing information (tirzepatide label, semaglutide label). The titration periods were roughly comparable, though tirzepatide's longer ramp means steady-state exposure was reached later. This matters when interpreting early time-point data.

Estimand Framework

SURPASS-2 used two estimands: a treatment-policy estimand (intention-to-treat, includes all data regardless of treatment discontinuation) and an efficacy estimand (on-treatment data only). The primary analysis used the treatment-policy estimand. The difference between the two was small, which suggests that the drug's real-world effectiveness tracks close to its on-treatment efficacy, a sign of decent tolerability and adherence over 40 weeks.

Results Beyond the Abstract

A1C Reduction

The <5.7% threshold is worth attention. That number represents a normal, non-diabetic A1C. Nearly half the patients on tirzepatide 15 mg reached it. The clinical meaning of "normoglycemia" in a treated T2D patient is debated (it does not mean the disease is reversed), but it does suggest a degree of glycemic control that was previously uncommon with any single injectable agent.

The HealthRX.com Practice-Translation Matrix

To make SURPASS-2 data actionable, we mapped results against three clinical decision points that practicing endocrinologists and PCPs face weekly:

Weight Loss

The weight separation between the 15 mg tirzepatide arm and semaglutide 1 mg was roughly 5.5 kg. That gap is large enough to influence body composition, insulin sensitivity, and patient-reported quality of life. It also positions tirzepatide as a dual-purpose agent in a way that prior GLP-1RAs were not, at least not at this magnitude in a T2D population.

Safety and Tolerability

Gastrointestinal adverse events were the most common side effects in all arms. Nausea occurred in 17.4% (5 mg), 19.8% (10 mg), and 22.1% (15 mg) of tirzepatide patients vs. 17.9% with semaglutide 1 mg. Diarrhea and vomiting followed similar patterns. Discontinuation rates due to adverse events were low across all groups (range: 3%, 7%), with the 15 mg tirzepatide arm at the higher end.

Hypoglycemia was rare. Clinically significant hypoglycemia (blood glucose <54 mg/dL) occurred in <1% of patients in any arm, consistent with the known safety profile of incretin-based therapies when not combined with sulfonylureas or insulin.

What Changed in Guidelines After SURPASS-2

ADA Standards of Care

The 2023 ADA Standards of Care updated its pharmacologic treatment algorithm to include dual GIP/GLP-1 agonists (tirzepatide) alongside GLP-1RAs as preferred options for patients with T2D who need additional glycemic control and have overweight or obesity. SURPASS-2 was cited as a key evidence source. The 2024 revision maintained this positioning.

Formulary and Access Shifts

Before SURPASS-2, most commercial formularies carried semaglutide (Ozempic) at a preferred tier. After the trial's publication and Mounjaro's FDA approval in May 2022, payer negotiations intensified. Some large pharmacy benefit managers began placing tirzepatide at a preferred or co-preferred tier. The practical result: patients now sometimes have better copay coverage for one agent over the other based on their specific plan, not on clinical evidence. Clinicians need to check formulary status before writing the prescription.

Real-World Prescribing Patterns

Prescription data from 2023 and 2024 show a rapid uptake of tirzepatide in T2D. IQVIA data indicate that tirzepatide captured a meaningful share of new GLP-1RA starts within 18 months of launch. SURPASS-2's head-to-head framing gave prescribers a direct comparison to cite when justifying prior authorization requests, which accelerated adoption.

Limitations the Authors Acknowledged

The original publication noted several limitations directly:

1. 40-week duration. Long enough to establish glycemic efficacy but not long enough to assess cardiovascular outcomes, durability of weight loss, or long-term safety signals.

2. Semaglutide 1 mg comparator only. The trial does not answer how tirzepatide compares to semaglutide 2 mg, oral semaglutide 14 mg, or other GLP-1RAs like dulaglutide.

3. Open-label design. Patients and investigators knew which treatment they received. This can introduce bias in subjective outcome reporting (nausea severity, quality of life) but is unlikely to meaningfully bias A1C, a laboratory-measured endpoint.

4. Population homogeneity. The trial enrolled predominantly White (56%) and Asian (28%) participants. Black and Hispanic patients were underrepresented relative to the populations who bear the highest T2D burden in the United States.

5. Metformin background. All patients were on metformin. The results may not generalize to patients on other background therapies (SGLT2 inhibitors, sulfonylureas, insulin).

Who in the Trial Population Matches Your Patient

The mean baseline characteristics were: age ~56, BMI ~34, diabetes duration ~8.6 years, A1C ~8.3%. Patients were on stable metformin at ≥1 to 500 mg/day.

If your patient fits this profile, the SURPASS-2 data apply fairly directly. If your patient diverges meaningfully (longer diabetes duration, already on insulin, BMI <30, eGFR <45), you are extrapolating. The SURPASS program includes trials in those populations (SURPASS-3 for insulin-naive patients on metformin with or without SGLT2i, SURPASS-4 for patients on 1-3 oral agents with increased CV risk, SURPASS-5 for patients on basal insulin), but this specific trial does not cover them.

Frequently asked questions

›How much better was tirzepatide than semaglutide 1 mg on A1C in SURPASS-2?

Tirzepatide reduced A1C by 2.01% (5 mg), 2.24% (10 mg), and 2.30% (15 mg) from a baseline of ~8.3%, compared to 1.86% with semaglutide 1 mg. The difference ranged from 0.15 to 0.45 percentage points depending on the tirzepatide dose. All three doses achieved statistical superiority (p < 0.001).

›Does SURPASS-2 prove tirzepatide is better than all doses of semaglutide?

No. SURPASS-2 compared tirzepatide to semaglutide 1 mg only. It does not provide evidence against semaglutide 2 mg (Ozempic's higher dose) or semaglutide 2.4 mg (Wegovy, approved for obesity). A direct comparison at those doses has not been published in a randomized trial.

›Was SURPASS-2 double-blinded?

No. The trial used an open-label design. Participants and investigators knew which drug they received. The primary endpoint (A1C) is a lab value not subject to placebo effects, which limits the impact of unblinding on the main outcome.

›Did tirzepatide cause more GI side effects than semaglutide in SURPASS-2?

GI side effects were common in all arms. Nausea rates were similar between tirzepatide 5 mg (17.4%) and semaglutide 1 mg (17.9%), but rose modestly at higher tirzepatide doses (up to 22.1% at 15 mg). Discontinuation rates due to adverse events remained low across all groups.

›How much weight did patients lose in SURPASS-2?

Mean weight loss was 7.6 kg (5 mg), 9.3 kg (10 mg), and 11.2 kg (15 mg) with tirzepatide vs. 5.7 kg with semaglutide 1 mg over 40 weeks. The 15 mg dose produced roughly twice the weight loss seen with semaglutide 1 mg.

›Have guidelines changed because of SURPASS-2?

Yes. The ADA Standards of Care (2023 onward) now list tirzepatide alongside GLP-1RAs as a preferred injectable option for T2D patients with overweight or obesity who need additional glycemic control beyond metformin. SURPASS-2 is cited as supporting evidence.

›Who should NOT be prescribed tirzepatide based on SURPASS-2 data?

SURPASS-2 excluded patients with a personal or family history of medullary thyroid carcinoma or MEN2 syndrome, consistent with the class labeling for incretin-based therapies. Patients with severe GI disease, recent pancreatitis, or type 1 diabetes were also excluded. The FDA label carries a boxed warning about thyroid C-cell tumors based on rodent studies.

›Does SURPASS-2 address cardiovascular outcomes?

No. The trial was 40 weeks long and not powered for cardiovascular events. The dedicated cardiovascular outcomes trial (SURPASS-CVOT) is a separate study. Interim and preliminary data from that trial have been presented, but SURPASS-2 itself does not answer the CV question.

›Can SURPASS-2 results be applied to patients not on metformin?

With caution. All SURPASS-2 participants were on metformin at ≥1 to 500 mg/day. The magnitude of A1C reduction may differ in patients on other backgrounds (insulin, SGLT2 inhibitors, sulfonylureas). Other trials in the SURPASS program tested those combinations separately.

›Is the cost of tirzepatide vs semaglutide addressed by SURPASS-2?

The trial does not include cost-effectiveness data. List prices for Mounjaro and Ozempic are similar, but net cost to patients varies widely by insurer, formulary tier, and manufacturer copay card availability. Cost should be checked at the point of prescribing.

References

1. Frias JP, Davies MJ, Rosenstock J, et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. N Engl J Med. 2021;385(6):503-515. PubMed
2. Lingvay I, Hansen T, Macura S, et al. Superior efficacy of semaglutide 2.0 mg versus 1.0 mg in SUSTAIN FORTE. Diabetes Care. 2021;44(9):2163-2170. PubMed
3. American Diabetes Association Professional Practice Committee. Standards of Care in Diabetes, 2023. Diabetes Care. 2023;46(Suppl 1). PubMed
4. Tirzepatide (Mounjaro) prescribing information. Eli Lilly and Company. FDA Label
5. Semaglutide (Ozempic) prescribing information. Novo Nordisk. FDA Label
6. Nicholls SJ, Bhatt DL, Buse JB, et al. Tirzepatide and cardiovascular outcomes in type 2 diabetes: SURPASS-CVOT. N Engl J Med. 2024. PubMed